Weekly vs. q3w docetaxel doses in patients with HRPC. NK cell activity data (CROSBI ID 525705)
Prilog sa skupa u zborniku | sažetak izlaganja sa skupa | međunarodna recenzija
Podaci o odgovornosti
Čustović, Zajim ; Kaštelan, Maja ; Kraljić, Ivo ; Kovačić, Ksenija ; Tarle, Marko.
engleski
Weekly vs. q3w docetaxel doses in patients with HRPC. NK cell activity data
Follow-up of HRPC patients treated with docetaxel combinations is obstracted by heterogeneity of bone scans and by the huge range of variations in the ability of such tumors to secrete PSA. Thus these parameters are rather difficult to use in monitoring the response of the therapy applied. We reported the use of Nk cell activity data, that indicate the presence of tumor cells in the circulation, as a valuable prognostic parameter that may be added to all others in the evaluation of the used treatment.
HRPC; docetaxel therapy; weekly and q3w; NK cell data as monitoring prognosticator
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o prilogu
146-146-x.
2006.
objavljeno
Podaci o matičnoj publikaciji
Robert H Getzenberg, PhD, Johns Hopkins School of Medicine
Baltimore (MD): SBUR, Society for Basic Urologic Research, USA
Podaci o skupu
SBUR 2006 Annual Meeting, November 16-19, 2006, Phoenix, AZ, USA
poster
16.11.2006-19.11.2006
Phoenix (AZ), Sjedinjene Američke Države